MGMT and glioblastoma: This phase I study was designed following xenograft studies that revealed a chemosensitizing effect of ACZ in experimental GBM that have a methylated MGMT promoter.10 Here, an initial cohort of 24 patients was enrolled with the primary outcome being safety and tolerability in patients with newly diagnosed, MGMT promoter-methylated GBM.